Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXD01
- Development stage
- Preclinical
- Lead developer
- neoX Biotech
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
NXD01 is an orally bioavailable, heterobifunctional proteolysis-targeting chimera (PROTAC) designed to degrade the WEE1 protein. Developed by neoX Biotech using its AI-empowered neoDegrader platform, NXD01 utilizes the cereblon (CRBN) E3 ubiquitin ligase to selectively target and degrade WEE1. WEE1 is a critical tyrosine kinase that regulates cell cycle checkpoints by phosphorylating CDK1, preventing premature entry into mitosis. By degrading WEE1, NXD01 induces mitotic catastrophe and apoptosis in cancer cells. In preclinical studies, NXD01 demonstrated potent anti-proliferative activity across multiple gynecological cancer cell lines and showed robust in vivo antitumor efficacy in uterine leiomyosarcoma xenograft models.
02
Targets
CRBN (Cereblon)WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on NXD01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXD01.